The innovative catheter that meets all the needs of vein ablation therapy
Doctors and patients have been asking for a pain-free, effective, non-thermal, and non-tumescent vein ablation device. We answered.
About BASIS™
What We Do
BASIS™ Medical is a start-up medical device company that provides a materially safer, more comfortable, clinically effective, and industry-changing endovenous vein ablation catheter for the treatment of Chronic Venous Insufficiency (CVI) disease of the legs. The BASIS™ catheter is a true disruptive technology.
BASIS™ Medical’s vision is to be the dominant, worldwide supplier of the next generation of vein ablation catheters to meet the current needs of patients seeking treatment for CVI as well as physicians treating CVI. Current annual market opportunity (US Only) is approximately $1 Billion and growing. The current vein-ablation therapies offered have material and sometimes dangerous drawbacks. Doctors have been searching for a device that can treat CVI in the legs with an increased comfort and safety profile. The BASIS™ Catheter is that device.
The BASIS™ catheter meets the ever-increasing demand for a pain-free (non-thermal, and non-tumescent), safer, clinically effective vein-ablation device for the treatment of CVI. In other words, the BASIS™ Catheter meets the needs of physicians and patients by eliminating the drawbacks associated with existing CVI therapies in a cost-effective and efficient manner.
The BASIS™ Catheter represents the first-ever device that will not only be safer, more comfortable, and as clinically effective as any currently used/FDA approved chemical sclerosant, but will also ensure that providing physicians maintain their current revenue stream from health insurance companies.
“Advances in medicine involve improved patient safety, comfort, and outcomes. The next big advance in the treatment of chronic venous insufficiency (CVI) is here now and it is the BASIS™ catheter system.”
How It Works
BASIS™ is an endovenous, chemical ablation procedure for the treatment of superficial venous insufficiency, which uses a dual-balloon system inflated to isolate a specific segment of a diseased blood vessel, remove the blood therein, instill an FDA approved ablative chemical (sclerosant) for a specified period of time, then remove the sclerosant. Finally, the balloons are deflated and the catheter repositioned for the next treatment segment.
What Sets BASIS™ Apart
No More Needles
No more painful needle sticks to deliver tumescent anesthesia.
Shorter Recovery
Current treatment options can leave you with 2 weeks of recovery time
Patented Solution
We have filed for patent protection on the procedure and the BASIS™ catheter.
Better Results
Look better and feel better for longer. BASIS™ gives you the confidence you miss.
Contact Us
Get In Touch
BASIS™ is a best in class solution to a problem that affects 30-35 million Americans. Ready to get in on the future of CVI treatment? For more information or to speak with our team, please share your information and we will be in touch.
For more information or to speak with our team, please contact Tomas Levinton: